Sanofi Withdraws Emerflu Application - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Sanofi Withdraws Emerflu Application

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Sanofi Pasteur (Paris) has formally withdrawn its application to the European Medicines Agency (EMA) for a centralized marketing authorization for its pandemic influenza vaccine Emerflu. The vaccine was intended to help prevent influenza during an officially declared pandemic. A core pandemic dossier was submitted in the context of preventing influenza in an officially declared pandemic, according to the mock-up vaccine procedure. Sanofi Pasteur withdrew the application because the EMA’s Committee for Medicinal Products for Human Use (CHMP) said that the data did not allow the committee to conclude a positive benefit–risk balance, according to the EMA.

Sanofi submitted the application for marketing authorization in April 2007. However, the CHMP issued a negative opinion for the drug in March 2009 because of concerns about the vaccine’s ability to trigger the production of enough antibodies against the flu virus.

“According to criteria laid down by the CHMP, a mock-up vaccine needs to bring about protective levels of antibodies in at least 70% of people for it to be considered suitable,” stated a Q&A from the EMA concerning Emerflu. “Because antibody production following Emerflu administration was below this level in the main studies (less than 40% in participants aged below 60 years), the CHMP was concerned that Emerflu was not suitable for use as a mock-up vaccine.”

Similar results were also seen in people who received the drug containing a different strain of flu virus, and studies looking at the effects of a third dose produced contradictory results, thus raising concerns about the vaccine’s low immunogenicity, regardless of the strain of virus included.

More information about the withdrawal, including the withdrawal letter from the company, will be published on the EMA website after the next CHMP meeting on December 13–16, 2010.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here